25 November 2015 - Roche announced today that the European Commission has approved Cotellic (cobimetinib) for use in combination with Zelboraf (vemurafenib) for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

For more details, go to: http://www.roche.com/media/store/releases/med-cor-2015-11-25.htm